Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free CELU Stock Alerts

Celularity (CELU) Competitors

Celularity logo
$0.80 +0.03 (+4.32%)
As of 08/21/2026 03:59 PM Eastern
Compare

CELU vs. ATRA, SERA, TELO, ACET, and ACRV

Should you buy Celularity stock or one of its competitors? Celularity's main competitors and comparable companies include Atara Biotherapeutics (ATRA), Sera Prognostics (SERA), Telomir Pharmaceuticals (TELO), Adicet Bio (ACET), and Acrivon Therapeutics (ACRV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celularity compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Atara Biotherapeutics had 2 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 0 mentions for Celularity. Atara Biotherapeutics' average media sentiment score of 0.51 beat Celularity's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Atara Biotherapeutics Positive
Celularity Neutral

Atara Biotherapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Celularity has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential downside of 2.06%. Celularity has a consensus price target of $6.00, indicating a potential upside of 649.91%. Given Celularity's higher possible upside, analysts clearly believe Celularity is more favorable than Atara Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Atara Biotherapeutics has a net margin of -269.42% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atara Biotherapeutics-269.42% -79.12% -73.01%
Celularity -345.45%N/A -77.94%

Atara Biotherapeutics has higher earnings, but lower revenue than Celularity. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara Biotherapeutics$6.19M15.72$32.69M-$1.18N/A
Celularity$26.55M0.87-$91.72M-$3.33N/A

Summary

Atara Biotherapeutics beats Celularity on 9 of the 14 factors compared between the two stocks.

How does Celularity compare to Sera Prognostics?

Celularity (NASDAQ:CELU) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Celularity has a net margin of -345.45% compared to Sera Prognostics' net margin of -47,475.72%. Celularity's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celularity-345.45% N/A -77.94%
Sera Prognostics -47,475.72%-46.71%-34.06%

Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 649.91%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 157.01%. Given Celularity's higher possible upside, analysts plainly believe Celularity is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

19.0% of Celularity shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sera Prognostics has lower revenue, but higher earnings than Celularity. Sera Prognostics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$26.55M0.87-$91.72M-$3.33N/A
Sera Prognostics$80K1,047.53-$31.93M-$0.67N/A

In the previous week, Sera Prognostics had 4 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Sera Prognostics and 0 mentions for Celularity. Sera Prognostics' average media sentiment score of 0.24 beat Celularity's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company Overall Sentiment
Celularity Neutral
Sera Prognostics Neutral

Celularity has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Sera Prognostics beats Celularity on 10 of the 16 factors compared between the two stocks.

How does Celularity compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

19.0% of Celularity shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Telomir Pharmaceuticals has higher earnings, but lower revenue than Celularity. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.91N/A
Celularity$26.55M0.87-$91.72M-$3.33N/A

In the previous week, Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.

Company Overall Sentiment
Telomir Pharmaceuticals Neutral
Celularity Neutral

Telomir Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Celularity has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -102.70% -90.75%
Celularity -345.45%N/A -77.94%

Celularity has a consensus price target of $6.00, suggesting a potential upside of 649.91%. Given Celularity's higher possible upside, analysts plainly believe Celularity is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Celularity beats Telomir Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Celularity compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Celularity has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adicet BioN/AN/A-$116.80M-$11.45N/A
Celularity$26.55M0.87-$91.72M-$3.33N/A

Adicet Bio has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Adicet Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Adicet BioN/A -74.90% -60.87%
Celularity -345.45%N/A -77.94%

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Celularity's average media sentiment score of 0.00 beat Adicet Bio's score of -1.00 indicating that Celularity is being referred to more favorably in the news media.

Company Overall Sentiment
Adicet Bio Negative
Celularity Neutral

Adicet Bio presently has a consensus price target of $46.80, suggesting a potential upside of 409.25%. Celularity has a consensus price target of $6.00, suggesting a potential upside of 649.91%. Given Celularity's higher possible upside, analysts clearly believe Celularity is more favorable than Adicet Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adicet Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Adicet Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Celularity has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

Celularity beats Adicet Bio on 8 of the 15 factors compared between the two stocks.

How does Celularity compare to Acrivon Therapeutics?

Celularity (NASDAQ:CELU) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 649.91%. Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 510.86%. Given Celularity's higher possible upside, equities research analysts plainly believe Celularity is more favorable than Acrivon Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Acrivon Therapeutics has lower revenue, but higher earnings than Celularity. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$26.55M0.87-$91.72M-$3.33N/A
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

Celularity has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Acrivon Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celularity-345.45% N/A -77.94%
Acrivon Therapeutics N/A -70.14%-61.60%

In the previous week, Acrivon Therapeutics had 7 more articles in the media than Celularity. MarketBeat recorded 7 mentions for Acrivon Therapeutics and 0 mentions for Celularity. Acrivon Therapeutics' average media sentiment score of 0.35 beat Celularity's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Celularity Neutral
Acrivon Therapeutics Neutral

Summary

Acrivon Therapeutics beats Celularity on 10 of the 15 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELU vs. The Competition

Export
MetricCelularityBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$22.20M$3.95B$7.26B$12.77B
Dividend YieldN/A3.64%2.54%11.08%
P/E Ratio-0.2411.70273.1824.24
Price / Sales0.871,398.90689.05129.21
Price / CashN/A103.2976.8953.23
Price / Book-0.6117.9013.456.38
Net Income-$91.72M-$12.50M$3.47B$348.73M
7 Day Performance14.99%3.28%2.08%0.08%
1 Month Performance2.58%7.76%6.10%2.91%
1 Year Performance-78.89%55.21%24.99%17.19%

Celularity Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELU
Celularity
1.7998 of 5 stars		$0.80
+4.3%		$6.00
+649.9%		-77.8%$22.20M$26.55MN/A220
ATRA
Atara Biotherapeutics
1.01 of 5 stars		$8.94
+3.8%		$9.50
+6.3%		-15.6%$80.55M$120.77MN/A330
SERA
Sera Prognostics
2.9677 of 5 stars		$1.99
-1.0%		$5.50
+176.4%		-10.1%$77.93M$80KN/A120
TELO
Telomir Pharmaceuticals
0.4127 of 5 stars		$1.13
-3.4%		N/A-24.7%$77.72MN/AN/A1
ACET
Adicet Bio
2.7626 of 5 stars		$8.23
+1.5%		$46.80
+468.7%		-15.9%$76.93MN/AN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
One Ticker Tied to a Major White House Move You Should Know
Larry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. ...
Brownstone Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel